“Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials”, J of Skin, vol. 6, no. 6, p. s71, Nov. 2022, doi: 10.25251/skin.6.supp.71.